TNFRSF17 and Miyoshi myopathy: More recently, patients with advanced MM can also be treated with T‐cell redirecting bispecific antibodies (BsAb) following the approval of the off‐the‐shelf available T‐cell engaging BsAb teclistamab, which binds to both BCMA on the tumor cells and CD3 on T cells (for details next sections).